Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy
Menée sur deux cohortes indépendantes incluant au total 174 patients atteints d'un mélanome traité par immunothérapie anti-CTLA4, cette étude met en évidence une association entre des mutations somatiques des gènes SERPINB3 et SERPINB4 et la survie des patients
Immune checkpoint blockade has shown significant promise as an anticancer treatment, yet the determinants of response are not completely understood. Here we show that somatic mutations in SERPINB3 and SERPINB4 are associated with survival after anti-CTLA4 immunotherapy in two independent cohorts of patients with melanoma (n = 174). Interestingly, serpins are homologs of the well-known ovalbumin antigen and are associated with autoimmunity. Our findings have implications for the personalization of immunotherapy.
Nature Genetics , résumé, 2015